IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

February 11, 2008

Last Updated Date

November 19, 2008

Start Date ^†

September 2005

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

Complete list of historical versions of study NCT00620880 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy

Official Title ^†

Performance of CAST With Different Allergens in Patients With Cat Dander Allergy

Brief Summary

Primary objective of the trial:

To determine at which concentration the fusion protein MAT Fel d1 degranulates basophils of cat dander allergic patients, in comparison to a cat dander extract and to Fel d1 alone

Detailed Description

Study Phase

Study Type ^†

Observational

Study Design ^†

Prospective

Condition ^†

Allergy to Cats

Intervention ^†

Behavioral: Blood sample

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Enrollment ^†

Completion Date

September 2006

Primary Completion Date

Eligibility Criteria ^†

Inclusion criteria: 1. Patient with Cat Dander Allergy evidenced by positive history 2. Age: 18 to 75 years

Exclusion criteria: 1. Use of oral corticosteroids, Chromoglycin, Ketotifen, or any immunosuppressive drugs within the last 2 months 2. Psychiatric disorder resulting in malcompliance 3. Neg. IgE to Cat dander

Gender

Both

Ages

18 Years to 75 Years

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

Switzerland

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00620880

Responsible Party

University Hospital Zürich, University of Zurich

Secondary IDs ^††

Study Sponsor ^†

University of Zurich

Collaborators ^††

ImVision AG

Investigators ^†

Study Director:

01 Studienregister MasterAdmins

UniversitaetsSpital Zuerich

Information Provided By

University of Zurich

Verification Date

November 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.